CD274 and neoplasm: Programmed death-ligand 1 (PD-L1) expression, deficient mismatch repair (dMMR), microsatellite instability (MSI), and tumor mutational burden (TMB) have emerged as clinically relevant predictive biomarkers for ICI efficacy across tumor types (6–13).